Clinical Trial Update: Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study evaluating schedule de-escalation of 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer, wh…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• 177Lu-PSMA-617 (Lutetium-177 PSMA-617)

Snippet

Sponsor: Mayo Clinic | Conditions: Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Status: RECRUITING